Appendix B: Travel Vaccine Summary Table
Table B-01 is a quick reference for administering or prescribing travel-related vaccines. Before administering any vaccine, please pay particular attention to the dose and whether it is to be administered intramuscularly or subcutaneously. Also review detailed instructions, contraindications, precautions, and side effects under the specific vaccines discussed in this book or in the manufacturer’s prescribing information. For other immunizations, refer to the corresponding disease section in Chapter 3.
Table B-01. Travel vaccine summary
|VACCINE||TRADE NAME (MANUFACTURER)||AGE||DOSE||ROUTE||SCHED-
|Cholera CVD 103-HgR vaccine||Vaxchora (PaxVax)||18–64 y||100 mL (reconstituted)||Oral||1 dose||Undetermined1|
|Hepatitis A vaccine, inactivated||Havrix (GlaxoSmithKline)||1–18 y||0.5 mL (720 ELISA units)||IM||0 and 6–12 mo||None|
|≥19 y||1.0 mL (1,440 ELISA units)||IM||0 and 6–12 mo||None|
|Hepatitis A vaccine, inactivated||Vaqta (Merck & Co., Inc.)||1–18 y||0.5 mL (25 U)||IM||0 and 6–18 mo||None|
|≥19 y||1.0 mL (50 U)||IM||0 and 6–18 mo||None|
|Hepatitis B vaccine, recombinant2||Engerix-B (GlaxoSmithKline)||0–19 y||0.5 mL (10 μg HBsAg)||IM||0, 1, 6 mo||None|
|0–10 y (accelerated)||0.5 mL (10 μg HBsAg)||IM||0, 1, 2 mo||12 mo|
|11–19 y (accelerated)||1 mL (20 μg HBsAg)||IM||0, 1, 2 mo||12 mo|
|≥20 y (primary)||1 mL (20 μg HBsAg)||IM||0, 1, 6 mo||None|
|≥20 y (accelerated)||1 mL (20 μg HBsAg)||IM||0, 1, 2 mo||12 mo|
|>Hepatitis B vaccine, recombinant2||Recombivax HB (Merck & Co., Inc.)||0–19 y (primary)||0.5 mL (5 μg HBsAg)||IM||0, 1, 6 mo||None|
|11–15 y (adolescent accelerated)||1 mL (10 μg HBsAg)||IM||0, 4–6 mo||None|
|≥20 y (primary)||1 mL (10 μg HBsAg)||IM||0, 1, 6 mo||None|
|Combined hepatitis A and hepatitis B vaccine||Twinrix (GlaxoSmithKline)||≥18 y (primary)||1.0 mL (720 ELU HAV + 20μg HBsAg)||IM||0, 1, 6 mo||None|
|≥18 y (accelerated)||same as above||IM||0, 7, and 21–30 d||12 mo|
litis vaccine, inactivated
|Ixiaro (Valneva)||≥17 y||0.5 mL||IM||0, 28 d||≥1 year after primary series3|
|3-16 y||0.5 mL||IM||0, 28 d||Awaiting FDA assessment|
|2 mo–2 y||0.25 mL||IM||0, 28 d||Awaiting FDA assessment|
coccal polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D4)
|9–23 mo||0.5 mL||IM||0, 3 mo||If at continued risk5|
|2–55 y||0.5 mL||IM||1 dose|
coccal oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM4)
|2–12 mo||0.5 mL||IM||0, 2, 4, 10–13 mo||If at continued risk5|
|7–23 y||0.5 mL||IM||0,3 mo (2nd dose administered in 2nd year of life)|
|2–55 y||0.5 mL||IM||1 dose|
charide vaccine (MPSV4)
|Menomune (Sanofi Pasteur)||≥2 y||0.5 mL||SC||1 dose||If at continued risk5|
|Polio vaccine, inactivated||Ipol (Sanofi Pasteur)||≥18 y||0.5 mL||SC or IM||1 dose if patient has completed a pediatric series||Repeat boosters may be needed for long-term travelers to polio-affected countries; see Chapter 3, Polio|
|Rabies vaccine (human diploid cell)||Imovax (Sanofi Pasteur)||Any||1 mL||IM||Preexposure series: days 0, 7, and 21 or 28 d||None; see See Chapter 3, Rabies for postexposure immunization|
|Rabies vaccine (purified chick embryo cell)||RabAvert (Novartis)||Any||1 mL||IM||Preexposure series: days 0, 7, and 21 or 28 d||None; see See Chapter 3, Rabies for postexposure immunization|
|Typhoid vaccine (oral, live, attenuated)||Vivotif (PaxVax)||≥6 y||1 capsule7||Oral||0, 2, 4, 6 d||Repeat primary series after 5 y|
|Typhoid vaccine (Vi capsular polysaccharide)||Typhim Vi (Sanofi Pasteur)||≥2 y||0.5 mL||IM||1 dose||2 y|
|Yellow fever||YF-Vax (Sanofi Pasteur)||≥9 mo8||0.5 mL||SC||1 dose||Not recommended for most9|
Abbreviations: ELU, ELISA units of inactivated HAV; HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; IM, intramuscular; U, units HAV antigen; SC, subcutaneous.
1 In a clinical trial, vaccine efficacy was 90% at 10 days postvaccination and declined to 80% at 3 months postvaccination in prevention of severe diarrhea after oral cholera challenge. Long-term immunogenicity is unknown. Clinicians advising travelers who are at continued or repeated risk over an extended period may consider revaccination, although the appropriate interval and efficacy are unknown.
2 Consult the prescribing information for differences in dosing for hemodialysis and other immunocompromised patients.
3 If potential for Japanese encephalitis virus exposure continues. Data on the response to a booster dose administered ≥2 years after the primary series are not available.
4 If an infant is receiving the vaccine before travel, 2 doses may be administered as early as 8 weeks apart.
5 Revaccination with meningococcal conjugate vaccine (MenACWY-D or MenACWY-CRM) is recommended after 3 years for children who were previously vaccinated at ages 2 months through 6 years. Revaccination with meningococcal conjugate vaccine is recommended after 5 years for people who were previously vaccinated at ages 7–55 years and every 5 years thereafter for people who are at continued risk.
6 Revaccination with meningococcal polysaccharide vaccine is recommended for adults aged >55 years who remain at increased risk 5 years after the last dose. For adults aged >55 years who have received meningococcal conjugate vaccine previously or for whom multiple doses are anticipated (such as people with asplenia), meningococcal conjugate vaccine is preferred.
7 Must be kept refrigerated at 35.6°F–46.4°F (2°C–8°C); administer with cool liquid no warmer than 98.6°F (37°C).
8 Special considerations apply in deciding whether to administer yellow fever vaccine to people aged <9 months or ≥60 years. Please review Chapter 3, Yellow Fever before administration.
9 In 2014, the World Health Assembly (of the World Health Organization) adopted the recommendation to remove the 10-year booster dose requirement from the International Health Regulations as of July 2016. As of that time, a completed International Certificate of Vaccination or Prophylaxis is considered valid for the lifetime of the vaccinee. However, it is uncertain when and if all countries with yellow fever vaccination entry requirements will adopt this change. In February 2015, the Advisory Committee on Immunization Practices (ACIP) approved a new recommendation that a single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers. The ACIP also identified specific groups of travelers who should receive additional doses and others for whom additional doses may be considered. For full details see Chapter 3, Yellow Fever.
- Page created: May 31, 2017
- Page last updated: May 31, 2017
- Page last reviewed: May 31, 2017
- Content source: